ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mersana Therapeutics has raised $27 million in a round of financing led by New Enterprise Associates, a new investor in the biotech firm. Pfizer Venture Investments is also a new investor in the financing round, which will help Mersana develop antibody-drug conjugates (ADCs). Separately, Mersana has teamed with Adimab to offer integrated antibody discovery and ADC technology. Adimab will optimize antibodies for use with Mersana’s Fleximer polymer and linker technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X